China has introduced Order 818, a regulatory framework designed to accelerate local innovation and standardize the development environment for advanced therapies such as gene and cell therapies. The initiative signals Beijing’s intent to elevate the country's role in the global biotech landscape.
The framework targets advanced therapeutic medicinal products (ATMPs), including gene therapies, cell therapies, and tissue-engineered products. By establishing clearer rules for clinical trials, manufacturing, and quality control, China aims to foster a more predictable and efficient pathway from lab to market.
Order 818 is expected to streamline regulatory approvals and reduce development timelines for advanced therapies developed within China. The initiative aligns with the government's broader push for self-sufficiency in critical biotech sectors.
For global biotech firms, the framework both opens opportunities for collaboration and raises competitive stakes. Companies already investing in China's cell and gene therapy space may benefit from faster approvals, while Western firms could face stronger local rivals.
Patient access to cutting-edge therapies could improve if Order 818 successfully accelerates domestic development, though experts caution that implementation details and enforcement will determine its real-world impact.